Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 May;67(5):989–995. doi: 10.1038/bjc.1993.181

In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434.

V G Brunton 1, P Workman 1
PMCID: PMC1968438  PMID: 8388233

Abstract

The novel imidazoisoquinoline SDZ 62-434, originally identified as a platelet-activating factor (PAF) antagonist, has antiproliferative activity in a range of cell lines from human solid and haematological malignancies. Using an MTT cytotoxicity assay, IC50 values of 5 microM - 111 microM were observed following a 24 h exposure. Similar results were obtained using a clonogenic assay. The HT29 colon adenocarcinoma was particularly sensitive while the MCF-7 breast carcinoma was the most resistant in our panel. Only a 2-3 fold cross-resistance was seen in the doxorubicin and cisplatin resistant variants of the A2780 ovarian carcinoma; the drug did not modulate sensitivity to doxorubicin in either parent or resistant lines. No cross-resistance to SDZ 62-434 was seen in a doxorubicin-resistant MCF-7 variant. Cytotoxicity was not due to non-specific membrane lysis. The potent PAF antagonist WEB 2086 did not modulate SDZ 62-434 cytotoxicity, indicating no role for PAF receptors. Precursor incorporation studies in A2780 cells showed that DNA synthesis was inhibited more effectively than protein synthesis while RNA synthesis was unaffected. SDZ 62-434 inhibited both bombesin and platelet-derived growth factor-induced DNA synthesis in quiescent Swiss 3T3 cells. This suggests a possible role for SDZ 62-434 as an inhibitor of signal transduction in cancer cells.

Full text

PDF
989

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bazill G. W., Dexter T. M. An antagonist to platelet activating factor counteracts the tumoricidal action of alkyl lysophospholipids. Biochem Pharmacol. 1989 Jan 15;38(2):374–377. doi: 10.1016/0006-2952(89)90053-1. [DOI] [PubMed] [Google Scholar]
  2. Bazill G. W., Dexter T. M. Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells. Cancer Res. 1990 Dec 1;50(23):7505–7512. [PubMed] [Google Scholar]
  3. Berdel W. E., Bausert W. R., Weltzien H. U., Modolell M. L., Widmann K. H., Munder P. G. The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma. Eur J Cancer. 1980 Sep;16(9):1199–1204. doi: 10.1016/0014-2964(80)90179-6. [DOI] [PubMed] [Google Scholar]
  4. Berdel W. E., Korth R., Reichert A., Houlihan W. J., Bicker U., Nomura H., Vogler W. R., Benveniste J., Rastetter J. Lack of correlation between cytotoxicity of agonists and antagonists of platelet activating factor [paf-acether] in neoplastic cells and modulation of [3H]-paf-acether binding to platelets from humans in vitro. Anticancer Res. 1987 Nov-Dec;7(6):1181–1187. [PubMed] [Google Scholar]
  5. Berdel W. E. Membrane-interactive lipids as experimental anticancer drugs. Br J Cancer. 1991 Aug;64(2):208–211. doi: 10.1038/bjc.1991.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Casals-Stenzel J., Muacevic G., Weber K. H. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther. 1987 Jun;241(3):974–981. [PubMed] [Google Scholar]
  7. Danhauser-Riedl S., Felix S. B., Houlihan W. J., Zafferani M., Steinhauser G., Oberberg D., Kalvelage H., Busch R., Rastetter J., Berdel W. E. Some antagonists of platelet activating factor are cytotoxic for human malignant cell lines. Cancer Res. 1991 Jan 1;51(1):43–48. [PubMed] [Google Scholar]
  8. Danhauser S., Berdel W. E., Schick H. D., Fromm M., Reichert A., Fink U., Busch R., Eibl H., Rastetter J. Structure-cytotoxicity studies on alkyl lysophospholipids and some analogs in leukemic blasts of human origin in vitro. Lipids. 1987 Nov;22(11):911–915. doi: 10.1007/BF02535553. [DOI] [PubMed] [Google Scholar]
  9. Dicker P., Rozengurt E. Phorbol esters and vasopressin stimulate DNA synthesis by a common mechanism. Nature. 1980 Oct 16;287(5783):607–612. doi: 10.1038/287607a0. [DOI] [PubMed] [Google Scholar]
  10. Dive C., Watson J. V., Workman P. Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells. Cancer Res. 1991 Feb 1;51(3):799–806. [PubMed] [Google Scholar]
  11. Gescher A., Dale I. L. Protein kinase C--a novel target for rational anti-cancer drug design? Anticancer Drug Des. 1989 Aug;4(2):93–105. [PubMed] [Google Scholar]
  12. Lee J. S., Ong R., Yoo T. J., Chiang T. Binding of platelet activating factor by isolated membranes from U937 cells. Cell Immunol. 1990 Feb;125(2):415–425. doi: 10.1016/0008-8749(90)90095-9. [DOI] [PubMed] [Google Scholar]
  13. Lohmeyer M., Workman P. Lack of enantio-selectivity in the in vitro antitumour cytotoxicity and membrane-damaging activity of ether lipid SRI 62-834: further evidence for a non-receptor-mediated mechanism of action. Biochem Pharmacol. 1992 Aug 18;44(4):819–823. doi: 10.1016/0006-2952(92)90421-e. [DOI] [PubMed] [Google Scholar]
  14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  15. Nelson J., Donnelly M., Walker B., Gray J., Shaw C., Murphy R. F. Bombesin stimulates proliferation of human breast cancer cells in culture. Br J Cancer. 1991 Jun;63(6):933–936. doi: 10.1038/bjc.1991.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Noseda A., Godwin P. L., Modest E. J. Effects of antineoplastic ether lipids on model and biological membranes. Biochim Biophys Acta. 1988 Nov 3;945(1):92–100. doi: 10.1016/0005-2736(88)90366-5. [DOI] [PubMed] [Google Scholar]
  17. Plumb J. A., Milroy R., Kaye S. B. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 1989 Aug 15;49(16):4435–4440. [PubMed] [Google Scholar]
  18. Rozengurt E. Bombesin stimulation of mitogenesis. Specific receptors, signal transduction, and early events. Am Rev Respir Dis. 1990 Dec;142(6 Pt 2):S11–S15. doi: 10.1164/ajrccm/142.6_Pt_2.S11. [DOI] [PubMed] [Google Scholar]
  19. Seewald M. J., Olsen R. A., Sehgal I., Melder D. C., Modest E. J., Powis G. Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues. Cancer Res. 1990 Aug 1;50(15):4458–4463. [PubMed] [Google Scholar]
  20. Terashita Z., Tsushima S., Yoshioka Y., Nomura H., Inada Y., Nishikawa K. CV-3988 - a specific antagonist of platelet activating factor (PAF). Life Sci. 1983 Apr 25;32(17):1975–1982. doi: 10.1016/0024-3205(83)90049-8. [DOI] [PubMed] [Google Scholar]
  21. Tidwell T., Guzman G., Vogler W. R. The effects of alkyl-lysophospholipids on leukemic cell lines. I. Differential action on two human leukemic cell lines, HL60 and K562. Blood. 1981 Apr;57(4):794–797. [PubMed] [Google Scholar]
  22. Travers J. B., Li Q., Kniss D. A., Fertel R. H. Identification of functional platelet-activating factor receptors in Raji lymphoblasts. J Immunol. 1989 Dec 1;143(11):3708–3713. [PubMed] [Google Scholar]
  23. Uberall F., Oberhuber H., Maly K., Zaknun J., Demuth L., Grunicke H. H. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 1991 Feb 1;51(3):807–812. [PubMed] [Google Scholar]
  24. Vallari D. S., Austinhirst R., Snyder F. Development of specific functionally active receptors for platelet-activating factor in HL-60 cells following granulocytic differentiation. J Biol Chem. 1990 Mar 15;265(8):4261–4265. [PubMed] [Google Scholar]
  25. Valone F. H., Ruis N. M. Stimulation of tumour necrosis factor release by cytotoxic analogues of platelet-activating factor. Immunology. 1992 May;76(1):24–29. [PMC free article] [PubMed] [Google Scholar]
  26. Williams L. T. Signal transduction by the platelet-derived growth factor receptor. Science. 1989 Mar 24;243(4898):1564–1570. doi: 10.1126/science.2538922. [DOI] [PubMed] [Google Scholar]
  27. Workman P. Antitumor ether lipids: endocytosis as a determinant of cellular sensitivity. Cancer Cells. 1991 Aug;3(8):315–317. [PubMed] [Google Scholar]
  28. Workman P., Donaldson J., Lohmeyer M. Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells. Biochem Pharmacol. 1991 Jan 15;41(2):319–322. doi: 10.1016/0006-2952(91)90496-r. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES